Skip to main content

TELOMEROS Y ENFERMEDAD

SAF2017-82623-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Renal fibroblasts are involved in fibrogenic changes in kidney fibrosis associated with dysfunctional telomeres

  • Saraswati, Sarita
  • Martínez, Paula
  • Serrano, Rosa
  • Mejías, Diego
  • Graña-Castro, Osvaldo
  • Álvarez Díaz, Ruth
  • Blasco, Maria A
Tubulointerstitial fibrosis associated with chronic kidney disease (CKD) represents a global health care problem. We previously reported that short and dysfunctional telomeres lead to interstitial renal fibrosis; however, the cell-of-origin of kidney fibrosis associated with telomere dysfunction is currently unknown. We induced telomere dysfunction by deleting the Trf1 gene encoding a telomere-binding factor specifically in renal fibroblasts in both short-term and long-term life-long experiments in mice to identify the role of fibroblasts in renal fibrosis. Short-term Trf1 deletion in renal fibroblasts was not sufficient to trigger kidney fibrosis but was sufficient to induce inflammatory responses, ECM deposition, cell cycle arrest, fibrogenesis, and vascular rarefaction. However, long-term persistent deletion of Trf1 in fibroblasts resulted in kidney fibrosis accompanied by an elevated urinary albumin-to-creatinine ratio (uACR) and a decrease in mouse survival. These cellular responses lead to the macrophage-to-myofibroblast transition (MMT), endothelial-to-mesenchymal transition (EndMT), and partial epithelial-to-mesenchymal transition (EMT), ultimately causing kidney fibrosis at the humane endpoint (HEP) when the deletion of Trf1 in fibroblasts is maintained throughout the lifespan of mice. Our findings contribute to a better understanding of the role of dysfunctional telomeres in the onset of the profibrotic alterations that lead to kidney fibrosis.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Short telomeres in alveolar type II cells associate with lung fibrosis in post COVID-19 patients with cancer

  • Martínez, Paula
  • Sánchez-Vázquez, Raúl
  • Saha, Arpita
  • Rodriguez-Duque, Maria S.
  • Naranjo-Gonzalo, Sara
  • Osorio-Chávez, Joy S.
  • Villar Ramos, Ana V.
  • Blasco, María A.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic. The severity of COVID-19 increases with each decade of life, a phenomenon that suggest that organismal aging contributes to the fatality of the disease. In this regard, we and others have previously shown that COVID-19 severity correlates with shorter telomeres, a molecular determinant of aging, in patient’s leukocytes. Lung injury is a predominant feature of acute SARS-CoV-2 infection that can further progress to lung fibrosis in post-COVID-19 patients. Short or dysfunctional telomeres in Alveolar type II (ATII) cells are sufficient to induce pulmonary fibrosis in mouse and humans. Here, we analyze telomere length and the histopathology of lung biopsies from a cohort of alive post-COVID-19 patients and a cohort of age-matched controls with lung cancer. We found loss of ATII cellularity and shorter telomeres in ATII cells concomitant with a marked increase in fibrotic lung parenchyma remodeling in post- COVID-19 patients compared to controls. These findings reveal a link between presence of short telomeres in ATII cells and long-term lung fibrosis sequel in Post-COVID-19 patients., Research in the Blasco Lab is funded byFundación Botín and Banco Santander (Spain); Agencia Estatal de Investigación (AEI/MCI/10.13039/501100011033) with the project RETOS SAF2017-82623-R, cofunded by European Regional Development Fund (ERDF), “A way of making Europe”; Comunidad de Madrid with the Synergy Project COVIDPREclinicalMODels-CM and the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 882385) through the project ERC-AvG SHELTERINS. The CNIO, certified since 2011 as Severo Ochoa Centre of Excellence by AEI/MCI/10.13039/501100011033, is supported by the Spanish Government through the Instituto de Salud Carlos III (ISCIII). Research in the Villar Lab is funded by Agencia Estatal de Investigación RTI2018-095214-B-I00, Gobierno de Cantabria SUBVTC-2021-0011, Fomento de la transferencia de conocimiento en la Comunidad Autónoma de Cantabria 2020UCI22-PUB-000 and by Fundación IDIVAL INNVAL20/34., Peer reviewed
Docta Complutense
Publication Artículo científico (JournalArticle)

Depletion of the TRF1 telomere-binding protein leads to leaner mice with altered metabolic profiles

  • Ruano, Jessica Louzame
  • Bejarano, Leire
  • Serrano, Rosa
  • Diaz, Ruth Alvarez
  • Flores Landeira, Juana María
  • López, Ana Cayuela
  • Blasco, Maria A.
TRF1, a component of the telomere shelterin complex, plays crucial roles in telomere protection, telomere length regulation, and stemness. Here, we describe a previously unknown connection between TRF1 and metabolism. Telomere attrition has been linked to obesity. Our study reveals that Trf1-deficient mice exhibit a leaner phenotype, reduced adiposity, and improved glucose tolerance, even when subjected to a high-fat diet, independently of telomere shortening. These findings uncover a previously unknown role of TRF1 in regulating metabolism
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging

  • Piñeiro-Hermida, Sergio|||0000-0002-8915-5687
  • Autilio, Chiara
  • Martínez, Paula|||0000-0002-4655-5672
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Pérez-Gil, Jesús
  • Blasco, María A.|||0000-0002-4211-233X
Here, we show that physiological aging in mice leads to degenerative and fibrotic-like pathologies in the lung and that telomerase gene therapy prevents the onset of these pathologies. Our findings highlight telomerase activation as a potential therapeutic strategy for lung degenerative pathologies associated with aging. Short/dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant for telomere maintenance genes. However, it remains unknown whether physiological aging leads to short telomeres in the lung, thus leading to IPF with aging. Here, we find that physiological aging in wild-type mice leads to telomere shortening and a reduced proliferative potential of alveolar type II cells and club cells, increased cellular senescence and DNA damage, increased fibroblast activation and collagen deposits, and impaired lung biophysics, suggestive of a fibrosis-like pathology. Treatment of both wild-type and telomerase-deficient mice with telomerase gene therapy prevented the onset of lung profibrotic pathologies. These findings suggest that short telomeres associated with physiological aging are at the origin of IPF and that a potential treatment for IPF based on telomerase activation would be of interest not only for patients with telomerase mutations but also for sporadic cases of IPF associated with physiological aging.